Icon has launched a paperless solution for managing the clinical investigator financial disclosure forms mandated by the FDA.
XenoGesis and BioAscent plan to integrate their drug discovery offerings.
Progress has been made in pediatric drug development, but gaps still exist. What you should know about regulatory updates from an industry expert.
PolarityTE, offering scant details, acquired an unnamed CRO to expand its R&D programs and appointed a new veterinary officer.
MD Anderson detailed the success of their collaboration with BMS, which connects academic researchers to simultaneous I-O studies in a leukemia pilot.
Startup financier Accelerator Life Science Partners formed two new advisory panels to guide its business decisions, while expanding into San Diego.
Pfizer expanded its work with XtalPi to develop an AI platform to model small-molecule drugs as part of its discovery and development efforts.
Worldwide Clinical Trials and Datavant are collaborating on a neurodegenerative disease pilot study incorporating clinical data with real-world evidence.
Charles River Laboratories and The Michael J. Fox Foundation for Parkinson’s Research have extended their collaboration.
UCB and Science 37 will work to bring clinical trials out of traditional sites and into the home, using telemedicine and outcomes reported online.
Bristol-Myers Squibb and Flatiron Health signed a three-year agreement, planning to form an advisory board on real-world evidence in drug submissions.
.jpeg/original (1).jpeg?JMfLk.InCsaYsXAnTnDU1lFNz_X.mpbI&itok=SEoPjzZL "Bristol-Myers Squibb")